The nearly exclusive expression of CD79b on B cells and B-cell lymphomas, coupled with its internalization upon antigen binding, has sparked a growing interest in CD79b as a therapeutic target for antibody–drug conjugates (ADCs). The gene discussed is CD79B; the disease is B-cell non-Hodgkin lymphoma.